Ac2-26 (TFA)

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@H](C)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@H](C)NC(C)=O)=O)=O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O.[x]

[1]Wang LM, et al. Annexin 1-derived peptide Ac2-26 inhibits eosinophil recruitment in vivo via decreasing prostaglandin D₂. Int Arch Allergy Immunol. 2011;154 (2) :137-48.|[2]Liu L, et al. Ac2-26 Induces IKKβ Degradation Through Chaperone-Mediated Autophagy Via HSPB1 in NCM-Treated Microglia. Front Mol Neurosci. 2018 Mar 15;11:76.|[3]Gong J, et al. Ac2-26 ameliorates lung ischemia-reperfusion injury via the eNOS pathway. Biomed Pharmacother. 2019 Sep;117:109194.|[4]Luo Z, et al. Annexin-1 Mimetic Peptide Ac2-26 Suppresses Inflammatory Mediators in LPS-Induced Astrocytes and Ameliorates Pain Hypersensitivity in a Rat Model of Inflammatory Pain. Cell Mol Neurobiol. 2020 May;40 (4) :569-585.|[5]Zheng Y, et al. Annexin A1 (Ac2-26) -dependent Fpr2 receptor alleviates sepsis-induced acute kidney injury by inhibiting inflammation and apoptosis in vivo and in vitro. Inflamm Res. 2023 Feb;72 (2) :347-362.|[6]Qin CX, et al. Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction. Front Pharmacol. 2019 Apr 3;10:269.

IScience. 2023 Oct 6;26 (11) :108153.|Mater Today Bio. 2025 Mar 20:32:101690.|World J Gastroenterol. 2023 Jun 14;29 (22) :3422-3439.|Biol Reprod. 2025 Mar 26:ioaf060.|Cancer Cell. 2023 May 8;41 (5) :903-918.e8.|Exp Cell Res. 2026 Jan 1;454 (1) :114825.|Nat Nanotechnol. 2025 Aug 11.|Signal Transduct Target Ther. 2024 Aug 23;9 (1) :218.